HER WELL JOURNAL//LABS // INGREDIENT DATABASE
HER WELL JOURNAL LABS // INGREDIENT DATABASE

Magnesium Glycinate: Review for Sleep

CAS NO: 14783-68-7 | METABOLIC TARGET: Central GABA-A receptor agonism, NMDA receptor antagonism
TIER 1 (HUMAN RCTS)
⚕️ Medical DisclaimerThe database profiles and clinical trial breakdowns shared by Her Well Journal Labs are for educational purposes only. They do not constitute medical advice, diagnosis, or treatment. Always consult with your physician, endocrinologist, or qualified healthcare provider regarding any dietary supplement, active compound protocol, or metabolic concern.

Magnesium is a critical mineral co-factor involved in over 300 enzymatic reactions in the human body. In the context of midlife wellness, Magnesium Glycinate (magnesium bound to the amino acid glycine) is the preferred therapeutic form due to its superior intestinal absorption, high cellular bioavailability, and direct synergistic calming effects on the central nervous system.

Mechanism of Action (Circadian & Sleep Stabilization)

Hormonal fluctuations during menopause disrupt sleep architecture by reducing slow-wave (deep) sleep and increasing nocturnal awakenings. Magnesium Glycinate addresses these disturbances via two distinct biochemical mechanisms:

1. Central GABA-A Receptor Agonism

The glycine component acts as an inhibitory neurotransmitter in the brain. It binds to GABA-A receptors, potentiating the effects of gamma-aminobutyric acid (GABA)—the primary calming neurotransmitter. This relaxes the central nervous system, reduces sleep latency, and decreases nocturnal sympathetic spikes.

2. NMDA Receptor Antagonism

Magnesium acts as a natural calcium channel blocker at the NMDA (N-methyl-D-aspartate) glutamate receptor. By blocking glutamate (the primary excitatory neurotransmitter) from binding, magnesium prevents neuronal hyperexcitation, promoting physical and cognitive relaxation before sleep.

Human Clinical Trial Registry

TRIAL ID: PMID 23853124 (Double-Blind RCT)

  • Study Design: 8-week randomized, double-blind, placebo-controlled clinical trial on elderly subjects with insomnia.
  • Dosage: 500 mg daily of elemental magnesium.
  • Outcomes: Significant increase in sleep time, sleep efficiency, and concentration of circulating melatonin, alongside a significant decrease in serum cortisol levels compared to placebo.

TRIAL ID: PMID 21856382 (Bioavailability Study)

  • Study Design: Comparative pharmacokinetics of magnesium formulations.
  • Outcomes: Confirmed that magnesium bisglycinate/glycinate exhibits significantly higher serum absorption and lower gastrointestinal side effects (diarrhea) compared to inorganic forms like magnesium oxide.

Clinical Verdict

Magnesium Glycinate is a Tier 1 evidence-based intervention for sleep disruption and anxiety during the menopausal transition. Because elemental magnesium weight differs from total chelate weight, consumers must verify that the nutritional panel lists “elemental” magnesium bisglycinate/glycinate content rather than magnesium oxide blends.

REVIEWED PRODUCTS USING THIS INGREDIENT
Best Magnesium Supplements for Menopause Insomnia
LAB VERDICT: PASS
View Lab Verdict ➜